Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

104 sites for NCT04589845

AKT1 Mutation, +39 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +8 more drugs

immunotherapy, +1 more type

A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

155 sites for NCT03178552

ALK Alternative Transcription Site, +7 more biomarkers

Non-Small Cell Lung Carcinoma

alectinib, +2 more drugs

immunotherapy, +1 more type

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

78 sites for NCT02693535

AKT1 Mutation, +128 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +19 more conditions

abemaciclib, +23 more drugs

immunotherapy, +1 more type

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

25 sites for NCT02628067

Deficient DNA Mismatch Repair (dMMR), +6 more biomarkers

Anal Squamous Cell Carcinoma, +18 more conditions

pembrolizumab

immunotherapy

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioblastoma With Elevated Mutational Burden

264 sites for NCT04145115

TMB-High

Glioblastoma

ipilimumab, +1 more drug

immunotherapy

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

48 sites for NCT04632992

AKT1 Mutation, +17 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +11 more drugs

chemotherapy, +2 more types

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)

6 sites for NCT03767075

ATM Loss, +94 more biomarkers

Malignant Solid Tumor

atezolizumab

immunotherapy

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

10 sites for NCT03297606

ABL1 Fusion, +98 more biomarkers

B-Cell Non-Hodgkin Lymphoma, +2 more conditions

axitinib, +15 more drugs

immunotherapy, +1 more type

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

35 sites for NCT04591431

AKT1 Amplification, +59 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +19 more drugs

immunotherapy, +1 more type

CRAFT: The NCT-PMO-1602 Phase II Trial

4 sites for NCT04551521

AKT1 Amplification, +78 more biomarkers

Malignant Solid Tumor

alectinib, +6 more drugs

immunotherapy, +1 more type

A Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer

10 sites for NCT04486352

AKT1 Mutation, +12 more biomarkers

Endometrial Carcinoma

ado-trastuzumab emtansine, +5 more drugs

immunotherapy, +1 more type

Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype

1 site for NCT03718767

IDH1 Mutation, +2 more biomarkers

Glioma

nivolumab

immunotherapy